Zooms. Good indication...no sellers for the options...given time Anp will deliver.
There are about 7 to 10 big Pharma coy's doing very well in the $14 billion MS market...anp market could be a minimum of $1 billion +++
Like Mark said...anp1102 has proven it's potency clinically ...
Tysabri is as potent as atl1102 but anp and it's drug.is cheaper.safer and easier to. Administer.
Biogen owns Tecfidera and paid $3.25 for tysabri ...why?
Will BIOGEN shore up the ms market with atl1102
stem cell trial result out, page-32
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $70.32M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6865 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.8¢ | 159632 | 4 |
View Market Depth
| Last trade - 11.06am 25/07/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable